The data reinforces setmelanotide's efficacy across multiple rare obesity indications, supporting revenue growth trajectory. Monitor upcoming regulatory milestones for bivamelagon and PWS expansion. The stock has limited near-term catalyst beyond these data; long-term holders should watch for label expansion updates and quarterly sales figures.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $89.72entry
- T+1 · 5mo ago +6.81%α +8.06% · $95.83
- T+5 · 5mo ago +18.36%α +20.59% · $106.19
- T+20 · 4mo ago +22.56%α +22.36% · $109.96
- T+60 · 2mo ago +13.91%α +12.91% · $102.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals presented positive clinical and real-world data at ENDO 2026 for setmelanotide and bivamelagon across multiple rare obesity indications (acquired hypothalamic obesity, BBS, PWS). The data showed sustained weight loss, hunger reduction, and improved healthcare utilization, reinforcing the commercial thesis for its MC4R agonist platform. The stock market reaction is likely muted as the data is incremental and consistent with prior disclosures, but the breadth of positive readouts across indications supports the long-term pipeline value.
Key Facts
- Setmelanotide achieved -18.9% mean BMI reduction at 2.5 years in acquired HO patients (n=11).
- Oral bivamelagon showed -8.7% to -16.6% BMI reduction at 1 year across dose cohorts (n=26).
- 71.1% of pediatric and 71.4% of adult acquired HO patients achieved ≥1 weight category improvement with setmelanotide vs 13.6% and 6.7% on placebo.
- Real-world BBS data (n=286): 62% of adults achieved ≥10% body weight loss at 12 months; mean -9.8% weight loss in adults.
- PWS Phase 2 six-month results announced June 13 (separate press release).
- No new financial guidance, revenue, or EPS figures were disclosed.
Financial Impact
No financial figures disclosed; data supports continued commercial adoption and pipeline expansion for setmelanotide and bivamelagon.
Risk Factors
- Competition from other MC4R agonists and GLP-1 therapies for broader obesity.
- Regulatory setbacks for bivamelagon or PWS indication.
- Commercial execution risk for setmelanotide in acquired HO and BBS.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312120 |
Track record
26 reports on RYTM
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers